Abstract
Multiple sclerosis (MS) is characterized by chronic autoimmune inflammation of central nervous system (CNS), i. e. brain and spinal cord. Autoimmune inflammation of the CNS and periphery causes demyelination of axons ultimately leading to clinical symptoms such as gait imbalance, lack of coordination and paraplegia. Innate immune cells such as dendritic cells and neutrophils play a critical role in the initiation and progression of MS through upregulation of oxidants. Two prominent pathways that play important role in regulation of oxidant antioxidant balance are nuclear factor-erythroid factor 2-related factor 2 (Nrf2) and nuclear factor kappa light-chain-enhancer of activated B cells (NF-kappa B). Nrf2-mediated upregulation of antioxidants counteracts NF-kappa B-mediated oxidant generation. Therefore, this study evaluated the effects of nutraceutical drug, acetyl-11-keto13-boswellic acid (AKBA) in relapsing remitting model of experimental autoimmune encephelomyelitis (EAE). Efficacy of AKBA was explored on clinical symptoms, Nrf2, hemeoxygenase-1 (HO-1), NF-kappa B, inducible nitric oxide synthase (iNOS) in CNS and periphery of SJL/J mice. Our results show that expression ofp-NF-kappa B and iNOS is elevated, whereas expression of Nrf2 and HO-1 is decreased in CD11c + DCs and CNS, which is linked with appearance of clinical symptoms in immunized SJL/J mice. Treatment of immunized SJL/J mice with AKBA causes improvement of clinical symptoms and downregulation of inflammatory markers in CD11c + DCs (p-NF-kappa B, iNOS, and nitrotyrosine), and CNS (p-NF-kappa B, iNOS, nitrotyrosine,lipid peroxides, and total antioxidant capacity). Treatment of immunized SJL/J mice with AKBA also causes rectification of Nrf2 signaling in CD11c + DCs, and CNS. These results propose AKBA ameliorates EAE disease progression through rectification of Nrf2 signaling and attenuation of NF-kappa B pathway in RR model of EAE. Therefore, nutraceutical compound, AKBA may be therapeutically useful in RRMS.